PL EN


Preferences help
enabled [disable] Abstract
Number of results
Journal
2010 | 5 | 2 | 261-267
Article title

Association of osteoprotegerin and rankl levels with insulin resistance in pubertal obese children

Content
Title variants
Languages of publication
EN
Abstracts
EN
Osteoprotegerin (OPG)/“receptor activator of nuclear factor kappa B-ligand” (RANKL) system has an important role in the remodeling of bone through regulation of osteoclastogenesis. We aimed to detect OPG and RANKL levels, particularly in obese children in the pubertal period and to investigate whether these parameters correlate with insulin resistance in childhood. Our study included 66 obese children ranging in age from 9.1 to 16 years, and 22 non-obese children ranging in age from 10.5 to 16 years. Blood glucose, insulin, total cholesterol, HDL cholesterol, and LDL cholesterol levels were measured for all cases; HOMA-IR, Quicki index and atherogenic index were calculated. Serum OPG and RANKL levels were also measured. OPG and RANKL levels did not show any difference between obese and non-obese children (P>.05). No difference in these 2 parameters were observed among the children with and without insulin resistance (P>.05). No correlation could be established between the OPG, the HOMA-IR, Quick and atherogenic indices. Obesity and insulin resistance are believed to show their effect in the later period of life to become able to change some of the parameters.
Publisher

Journal
Year
Volume
5
Issue
2
Pages
261-267
Physical description
Dates
published
1 - 4 - 2010
online
17 - 4 - 2010
Contributors
  • Department of Pediatric Endocrinology, Gazi University Medical School, 06200, Ankara, Turkey, eyesilkaya@yahoo.co.uk
author
  • Department of Pediatric Endocrinology, Gazi University Medical School, 06200, Ankara, Turkey
  • Department of Pediatric Endocrinology, Gazi University Medical School, 06200, Ankara, Turkey
author
  • Department of Pediatric Endocrinology, Gazi University Medical School, 06200, Ankara, Turkey
  • Department of Pediatric Neurology, Gülhane Military Medical Academy, 06018, Ankara, Turkey
author
  • Department of Pediatric Endocrinology, Gazi University Medical School, 06200, Ankara, Turkey
References
  • [1] Alemzadeh R., Rising R., Lifshitz F., Obesity in Children, In: Lifshitz F., Editor. Pediatric Endocrinology. New York: Healthcare, 2007, 1–36
  • [2] Güngör N., Arslanian S.A., Nutritional disorders, In: Sperling M.A., Editor. Pediatric Endocrinology. Philadelphia: Saunders, 2002, 689–724
  • [3] Hasanoğlu A., Bideci A., Cinaz P., Tümer L., Unal S, Bone mineral density in childhood obesity., J. Pediatr. Endocrinol. Metab., 2000, 13, 307–311
  • [4] Rocher E., Chappard C., Jaffre C., Benhamou CL., Courteix D., Bone mineral density in prepubertal obese and control children: relation to body weight, lean mass, and fat mass., J. Bone. Miner. Metab., 2008, 26, 73–78 http://dx.doi.org/10.1007/s00774-007-0786-4[WoS][Crossref]
  • [5] Schoppet M., Preissner K.T., Hofbauer L.C., RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function., Arterioscler. Thromb. Vasc. Biol., 2002, 22, 549–553 http://dx.doi.org/10.1161/01.ATV.0000012303.37971.DA[Crossref]
  • [6] Browner W.S., Lui L.Y., Cummings S.R., Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women., J. Clin. Endocrinol. Metab., 2001, 86, 631–637 http://dx.doi.org/10.1210/jc.86.2.631[Crossref]
  • [7] Indridason O.S., Franzson L., Sigurdsson G., Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover., Osteoporos. Int., 2005, 16, 417–423 http://dx.doi.org/10.1007/s00198-004-1699-x[Crossref]
  • [8] Bucay N., Sarosi I., Dunstan C.R., Morony S., Tarpley J., Capparelli C., et al, Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification., Genes. Dev., 1998, 12, 1260–1268 http://dx.doi.org/10.1101/gad.12.9.1260[Crossref]
  • [9] Rogers A., Saleh G., Hannon R.A., Greenfield D., Eastell R., Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women., J. Clin. Endocrinol. Metab., 2002, 87, 4470–4475 http://dx.doi.org/10.1210/jc.2002-020396[Crossref]
  • [10] Rouster-Stevens KA, Langman CB, Price HE, Seshadri R, Shore RM, Abbott K, et al. RANKL:osteoprotegerin ratio and bone mineral density in children with untreated juvenile dermatomyositis. Arthritis Rheum 2007; 56: 977–983 http://dx.doi.org/10.1002/art.22433[Crossref][WoS]
  • [11] Franck H., Meurer T., Hofbauer L.C., Evaluation of bone mineral density, hormones, biochemical markers of bone metabolism, and osteoprotegerin serum levels in patients with ankylosing spondylitis., J. Rheumatol., 2004, 31, 2236–2241
  • [12] Min H., Morony S., Sarosi I., Dunstan C.R., Capparelli C., Scully S., et al., Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis., J. Exp. Med., 2000, 192, 463–474 http://dx.doi.org/10.1084/jem.192.4.463[Crossref]
  • [13] Anand D.V., Lahiri A., Lim E., Hopkins D., Corder R., The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects., J. Am. Coll. Cardiol., 2006, 47, 1850–1857 http://dx.doi.org/10.1016/j.jacc.2005.12.054
  • [14] Bundak R., Furman A., Gunoz H., Darendeliler F., Bas F., Neyzi O., Body mass index references for Turkish children., Acta. Paediatr., 2006, 95, 194–198 http://dx.doi.org/10.1080/08035250500334738[Crossref]
  • [15] Keskin M., Kurtoglu S., Kendirci M., Atabek M.E., Yazici C., Homeostasis model assessment is more reliable than the fasting glucose/insulin ratio and quantitative insulin sensitivity check index for assessing insulin resistance among obese children and adolescents., Pediatrics, 2005, 115, e500–503 http://dx.doi.org/10.1542/peds.2004-1921[Crossref]
  • [16] Buzi F., Maccarinelli G., Guaragni B., Ruggeri F., Radetti G., Meini A., et al., Serum osteoprotegerin and receptor activator of nuclear factors kB (RANKL) concentrations in normal children and in children with pubertal precocity, Turner’s syndrome and rheumatoid arthritis., Clin. Endocrinol. (Oxf)., 2004, 60, 87–91 http://dx.doi.org/10.1111/j.1365-2265.2004.01951.x[Crossref]
  • [17] Misra M., Soyka L.A., Miller K.K., Herzog D.B., Grinspoon S., De Chen D., et al., Serum osteoprotegerin in adolescent girls with anorexia nervosa., J. Clin. Endocrinol. Metab., 2003, 88, 3816–3822 http://dx.doi.org/10.1210/jc.2003-030088[Crossref]
  • [18] Ugur-Altun B., Altun A., Circulating leptin and osteoprotegerin levels affect insulin resistance in healthy premenopausal obese women., Arch. Med. Res., 2007, 38, 891–896 http://dx.doi.org/10.1016/j.arcmed.2007.04.013[Crossref][WoS]
  • [19] Oh E.S., Rhee E.J., Oh K.W., Lee W.Y., Baek K.H., Yoon K.H., et al., Circulating osteoprotegerin levels are associated with age, waist-to-hip ratio, serum total cholesterol, and low-density lipoprotein cholesterol levels in healthy Korean women., Metabolism, 2005, 54, 49–54 http://dx.doi.org/10.1016/j.metabol.2004.08.005[Crossref]
  • [20] Gannagé-Yared M.H., Yaghi C., Habre B., Khalife S., Noun R., Germanos-Haddad M., et al., Osteoprotegerin in relation to body weight, lipid parameters insulin sensitivity, adipocytokines, and C-reactive protein in obese and non-obese young individuals: results from both cross-sectional and interventional study., Eur. J. Endocrinol., 2008, 158, 353–359 http://dx.doi.org/10.1530/EJE-07-0797[Crossref][WoS]
  • [21] Szulc P., Hofbauer L.C., Heufelder A.E., Roth S., Delmas P.D., Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status., J. Clin. Endocrinol. Metab., 2001, 86, 3162–3165 http://dx.doi.org/10.1210/jc.86.7.3162[Crossref]
  • [22] Swolin-Eide D., Magnusson P., Hansson S., Bone mass, biochemical markers and growth in children with chronic kidney disease: a 1-year prospective study., Acta Paediatr., 2007, 96, 720–725 http://dx.doi.org/10.1111/j.1651-2227.2007.00236.x[WoS][Crossref]
  • [23] Angelopoulos N.G., Goula A., Katounda E., Rombopoulos G., Kaltzidou V., Kaltsas D., et al., Circulating osteoprotegerin and receptor activator of NF-kappaB ligand system in patients with betathalassemia major., J. Bone. Miner. Metab., 2007, 25, 60–67 http://dx.doi.org/10.1007/s00774-006-0728-6[Crossref]
  • [24] Ugur-Altun B., Altun A., Gerenli M., Tugrul A., The relationship between insulin resistances assessed by HOMA-IR and serum osteoprotegerin levels in obesity., Diabetes Res. Clin. Pract., 2005, 68, 217–222 http://dx.doi.org/10.1016/j.diabres.2004.10.011[Crossref]
  • [25] Gannagé-Yared M.H., Fares F., Semaan M., Khalife S., Jambart S., Circulating osteoprotegerin is correlated with lipid profile, insulin sensitivity, adiponectin and sex steroids in an ageing male population., Clin. Endocrinol. (Oxf)., 2006, 64, 652–658 http://dx.doi.org/10.1111/j.1365-2265.2006.02522.x[Crossref]
  • [26] Altun A., Ugur-Altun B., Tatli E., Decreased serum osteoprotegerin levels in patients with cardiac syndrome X., J. Endocrinol. Invest., 2004, 27, 839–843 [Crossref]
  • [27] Kim S.M., Lee J., Ryu O.H., Lee K.W., Kim H.Y., Seo J.A., et al., Serum osteoprotegerin levels are associated with inflammation and pulse wave velocity., Clin. Endocrinol. (Oxf)., 2005, 63, 594–598 http://dx.doi.org/10.1111/j.1365-2265.2005.02390.x[Crossref]
  • [28] Uemura H., Yasui T., Miyatani Y., Yamada M., Hiyoshi M., Arisawa K., et al., Circulating osteoprotegerin is associated with age and systolic blood pressure, but not with lipid profile or fasting glucose, in postmenopausal women., Menopause, 2008, 15, 180–184 [WoS]
  • [29] Dovio A., Allasino B., Palmas E., Ventura M., Pia A., Saba L., et al., Increased osteoprotegerin levels in Cushing’s syndrome are associated with an adverse cardiovascular risk profile., J. Clin. Endocrinol. Metab., 2007, 92, 1803–1808 http://dx.doi.org/10.1210/jc.2006-2283[Crossref]
  • [30] Rhee E.J., Oh K.W., Jung C.H., Lee W.Y., Oh E.S., Yun E.J., et al., The relationship between four single nucleotide polymorphisms in the promoter region of the osteoprotegerin gene and aortic calcification or coronary artery disease in Koreans., Clin. Endocrinol. (Oxf)., 2006, 64, 689–697 http://dx.doi.org/10.1111/j.1365-2265.2006.02530.x[Crossref]
Document Type
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.-psjd-doi-10_2478_s11536-009-0065-y
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.